123 related articles for article (PubMed ID: 22562987)
1. Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancer.
Krystal GW; Alesi E; Tatum JL
Mol Cancer Ther; 2012 Jul; 11(7):1385-8. PubMed ID: 22562987
[TBL] [Abstract][Full Text] [Related]
2. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
Berger AK; von Gall C; Abel U; Delorme S; Kloor M; Ose J; Weber TF; Stange A; Haag GM; Haberkorn U; Lordick F; Jäger D
BMC Cancer; 2012 Mar; 12():108. PubMed ID: 22439666
[TBL] [Abstract][Full Text] [Related]
3. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
4. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
Goshen E; Davidson T; Zwas ST; Aderka D
Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
[TBL] [Abstract][Full Text] [Related]
5. Early
Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
[TBL] [Abstract][Full Text] [Related]
6. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
9. Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer.
Choi YJ; Kim MJ; Lee BH; Kwon MJ; Hwang HS
Yonsei Med J; 2016 Jan; 57(1):232-7. PubMed ID: 26632406
[TBL] [Abstract][Full Text] [Related]
10. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
Liu FY; Yen TC; Wang JY; Yang TS
Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab: an arrow on target.
Kopper L
Pathol Oncol Res; 2010 Jun; 16(2):143-8. PubMed ID: 20432075
[TBL] [Abstract][Full Text] [Related]
12. 100% human monoclonal antibodies in oncology: hype or breakthrough?
Benay S; Fanciullino R; Mercier C; Iliadis A; Ciccolini J; Lacarelle B
Curr Top Med Chem; 2012; 12(15):1643-8. PubMed ID: 22978333
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET: for early prediction of response to the first-line chemotherapy in metastatic colorectal cancer?
Arslan C; Kilickap S
Ann Oncol; 2009 Jun; 20(6):1149-50; author reply 1150. PubMed ID: 19465432
[No Abstract] [Full Text] [Related]
14. FDG PET/CT evaluation of treatment response in patients with recurrent colorectal cancer.
Shamim SA; Kumar R; Shandal V; Halanaik D; Kumar G; Bal CS; Malhotra A
Clin Nucl Med; 2011 Jan; 36(1):11-6. PubMed ID: 21157200
[TBL] [Abstract][Full Text] [Related]
15. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.
Lin EH; Lenz HJ; Saleh MN; Mackenzie MJ; Knost JA; Pathiraja K; Langdon RB; Yao SL; Lu BD
Cancer Med; 2014 Aug; 3(4):988-97. PubMed ID: 24905030
[TBL] [Abstract][Full Text] [Related]
16. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
17. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
Hendlisz A; Golfinopoulos V; Garcia C; Covas A; Emonts P; Ameye L; Paesmans M; Deleporte A; Machiels G; Toussaint E; Vanderlinden B; Awada A; Piccart M; Flamen P
Ann Oncol; 2012 Jul; 23(7):1687-93. PubMed ID: 22112970
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab in colorectal cancer.
Wainberg ZA; Hecht JR
Expert Rev Anticancer Ther; 2007 Jul; 7(7):967-73. PubMed ID: 17627455
[TBL] [Abstract][Full Text] [Related]
19. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F
Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
